{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:48:27Z","timestamp":1791406107800,"version":"4.3.3"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.tjpad.2024.100008","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:27:38Z","timestamp":1736504858000},"page":"100008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable"],"prefix":"10.1016","volume":"12","author":[{"given":"Gill","family":"Farrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil D.","family":"Rabinovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.tjpad.2024.100008_bib0001","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMp1208061","article-title":"Brain amyloid imaging. FDA approval of florbetapir F18 Injection","volume":"367","author":"Yang","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2024.100008_bib0002","first-page":"25","article-title":"Performance of [18F]Flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease","volume":"9","author":"Salloway","year":"2017","journal-title":"Alz Dementia"},{"issue":"3","key":"10.1016\/j.tjpad.2024.100008_bib0003","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.tjpad.2024.100008_bib0004","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease","volume":"11","author":"Sabri","year":"2015","journal-title":"Alz Dementia"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100008_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alz Dementia"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100008_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N Eng J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2024.100008_bib0007","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early symptomatic Alzheimer disese: the TRAILBLAZER-ALZ2 randomised clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"Supple 24","key":"10.1016\/j.tjpad.2024.100008_bib0008","article-title":"Quantitative analysis of amyloid-PET from real-world practices: lessons learned from Imaging Dementia\u2014Evidence for Amyloid Scanning (IDEAS) study","volume":"19","author":"La Joie","year":"2023","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.tjpad.2024.100008_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2021.118775","article-title":"rPOP: robust PET only processing of community acquired heterogenous amyloid-PET data","volume":"246","author":"Iaccarino","year":"2022","journal-title":"Neuroimage"},{"issue":"7","key":"10.1016\/j.tjpad.2024.100008_bib0010","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s00259-021-05311-5","article-title":"A multisite analysis of the concordance between visual image interpretation and quantitative [18F]flutemetamol amyloid PET images","volume":"48","author":"Bucci","year":"2021","journal-title":"Eur J Nuc Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.tjpad.2024.100008_bib0011","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1007\/s00259-023-06279-0","article-title":"Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods","volume":"50","author":"Jovalekic","year":"2023","journal-title":"Eur J Nuc Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.tjpad.2024.100008_bib0012","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alz Dis"},{"issue":"10","key":"10.1016\/j.tjpad.2024.100008_bib0013","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","article-title":"Quantification of amyloid PET for future clinical use: a state-of-the-art review","volume":"49","author":"Pemberton","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.tjpad.2024.100008_bib0014","first-page":"12465","article-title":"Alzheimer's disease drug development pipeline: 2024","volume":"10","author":"Cummings","year":"2024","journal-title":"Alz Dementia"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100008_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","article-title":"Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers","volume":"11","author":"Savaldo","year":"2019","journal-title":"Alz Res Ther"},{"issue":"2","key":"10.1016\/j.tjpad.2024.100008_bib0016","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology","volume":"15","author":"La Joie","year":"2019","journal-title":"Alz Dementia"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100008_bib0017","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3\u201345 study: design of a prevention trial for Alzheimer's disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alz Dementia"},{"key":"10.1016\/j.tjpad.2024.100008_bib0018","unstructured":"Kisunla. Highlights of Prescribing Information. www.accessdata.fda.gov"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100008_bib0019","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","article-title":"Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F]flutemetamol amyloid PET study","volume":"48","author":"Hanseeuw","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.tjpad.2024.100008_bib0020","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1212\/WNL.0000000000011222","article-title":"Association of beta-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals","volume":"96","author":"van der Kall","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.tjpad.2024.100008_bib0021","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00259-020-05174-2","article-title":"Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent","volume":"48","author":"Collij","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.tjpad.2024.100008_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2020.117593","article-title":"Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies","volume":"226","author":"Bourgeat","year":"2021","journal-title":"Neuroimage"},{"key":"10.1016\/j.tjpad.2024.100008_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/alz.13883","article-title":"Stress testing the Centiloid: precision and variability of PET quantification of amyloid pathology","author":"Shekari","year":"2024","journal-title":"Alz Dementia"},{"issue":"5","key":"10.1016\/j.tjpad.2024.100008_bib0024","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2967\/jnumed.123.265766","article-title":"Quantitative brain amyloid PET","volume":"65","author":"Jagust","year":"2024","journal-title":"J Nuc Med"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:27:47Z","timestamp":1736504867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724006009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2274580724006009"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2024.100008","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2024.100008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100008"}}